

FIRST ANNOUNCEMENT

33rd Symposium on
**Medicinal Chemistry
in Eastern England**

Thursday 28th April, 2022
The Fielder Centre, Hatfield, UK




Image created by Louise Birch



#HatfieldMedChem22

W: www.rscbmcs.org/events/mcee/



RSC INTEREST GROUP
**BIOLOGICAL AND MEDICAL
CHEMISTRY SECTOR**

Synopsis:

The Symposium on Medicinal Chemistry in Eastern England, known colloquially as the "Hatfield MedChem" meeting, is a highly successful, long-standing, one-day meeting which runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists. The meeting aims to be informal and interactive for all those working in medicinal chemistry and drug discovery.

Organising Committee:



Adrian Hall
UCB (Treasurer)



Nicole Hamblin
Charles River (Chair)



David Hirst
MSD

Confirmed Speakers:

Martin Ambler (*LifeArc*)

The Development of PROTACs at LifeArc

Mark Charles (*Cancer Research UK*)

Discovery and optimisation of allosteric inhibitors of Glutaminase 1 (GLS1)

Laura Cleghorn (*University of Dundee*)

Discovery and first disclosure of DDU209 a potent and selective inhibitor of Lysyl tRNA synthetase for Tuberculosis

David Davies (*Antabio*)

Discovery of novel LasB inhibitors as an inhaled antivirulence therapy for the treatment of Pseudomonas aeruginosa infections in patients with chronic respiratory disease

Teresa de Haro (*UCB*)

Development and characterisation of 2-imino-hexahydropyrimidin-4-one derived Plasmepsin X inhibitors with in vivo anti-malarial activity

Samantha Hughes (*AstraZeneca*)

Next generation estrogen receptor degraders (SERDs): A decade of discovery at AstraZeneca

Nick Martin (*Domainex*)

Development of MAP4K4 Inhibitors for the Suppression of Cardiac Muscle Cell Death

Shane Rountree (*Almac Group*)

Discovery and development of first-in-class USP19 inhibitors for the treatment of metabolic and muscle-wasting diseases

Capps Green Zomaya Award Winner talk

Steve Watson (*Sosei Heptares*)

The discovery of novel GPR52 agonists: HTL0041178, a potential therapy for schizoaffective and related psychiatric disorders

Sponsors:

Sponsors are encouraged to support this popular event.


charles river

 evotec

COVID clause:

The face-to-face event is subject COVID changes and please be aware of government and local university requirements before planning a trip. This will also apply to your own government if you are travelling from overseas. RSC BMCS c/o Hg3 Conferences are not responsible for any expenses incurred.

Secretariat contact:

Hg3 Conferences
events@hg3.co.uk
+44 (0) 1423 529333

To find out more, visit the BMCS website by using the URL or by scanning the QR code here:

<https://www.rscbmcs.org/events/mcee/>



SCAN ME